NYLI Epoch Capital Growth Class C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
NYLI Epoch Capital Growth Class C MECEX
- NAV / 1-Day Return 14.96 / +0.47 %
- Total Assets 134.1M
-
Adj. Expense Ratio
2.160%
- Expense Ratio 2.160%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Global Large-Stock Growth
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 33%
USD | NAV as of Jun 10, 2026 | 1-Day Return as of Jun 10, 2026, 12:11 AM GMT+0
Morningstar’s Analysis MECEX
Will MECEX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the MECEX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of MECEX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 20.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
NVIDIA Corp | 3.46 | 5M | Technology |
Apple Inc | 2.29 | 3M | Technology |
EMCOR Group Inc | 2.12 | 3M | Industrials |
Fabrinet | 2.10 | 3M | Technology |
Alphabet Inc Class A | 1.97 | 3M | Communication Services |
Broadcom Inc | 1.90 | 3M | Technology |
Hoya Corp | 1.78 | 2M | Healthcare |
Taiwan Semiconductor Manufacturing Co Ltd | 1.66 | 2M | Technology |
AbbVie Inc | 1.57 | 2M | Healthcare |
West Pharmaceutical Services Inc | 1.54 | 2M | Healthcare |
United States